IDO1 and cancer: There is significant evidence that tumor cells can take advantage of IFN-γ as an inducer of pro-tumor effects, through upregulation of IDO and PD-L1 expression in cancer, stromal and myeloid cells and recruitment of Tregs cell and MDSCs to avoid immune recognition and impair the antitumor immunity of effector T cell [51].